Evolutec's rEV131 fails in Ph II inflammation trial
UK biopharmaceutical firm Evolutec says that, as a result of a failed Phase II trial, no further investment will be made in its lead product candidate rEV131. The drug did not meet its primary endpoints in a program that examined it as a treatment for the control of post-cataract surgery inflammation.
The study compared twice-daily dosing of rEV131 with a four times-a-day dosing regimen of the standard treatment prednisolone, and placebo. Analysis of the data revealed that there were no significant differences in therapeutic effect between rEV131 and placebo, whereas prednisolone demonstrated the expected level of efficacy.
Second failure at Phase II
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze